日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Efficacy and safety of antibody-drug conjugates in the treatment of advanced urological cancers: a systematic review and a meta-analysis

抗体药物偶联物治疗晚期泌尿系统癌症的疗效和安全性：系统评价和荟萃分析

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2025.1583654
Liu, Tian; Xie, Xiao; Ren, Yangz-Zi; Li, Zongyu; Cai, Maoping; Yu, Yuzhong; Zhuo, Lin
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Correction: ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer

更正：ELOVL2介导的AR稳定作用导致前列腺癌对恩扎卢胺产生耐药性

期刊:Frontiers in Cell and Developmental Biology
影响因子:4.3
doi:10.3389/fcell.2025.1646699
Cen, Jinpeng; Guo, Jiading; Zeng, Xianzi; Song, Xianlu; Ge, Shengdong; Chen, Mingkun; Li, Qianyi; Yu, Yuzhong; Lv, Daojun; Zhao, Shanchao
肿瘤
前列腺癌
肿瘤免疫
发表日期：2025
文献求助 收藏

ELOVL2 mediated stabilization of AR contributes to enzalutamide resistance in prostate cancer.

ELOVL2 介导的 AR 稳定作用导致前列腺癌对恩扎卢胺产生耐药性

期刊:Frontiers in Cell and Developmental Biology
影响因子:4.3
doi:10.3389/fcell.2025.1598400
Cen Jinpeng, Guo Jiading, Zeng Xianzi, Song Xianlu, Ge Shengdong, Chen Mingkun, Li Qianyi, Yu Yuzhong, Lv Daojun, Zhao Shanchao
肿瘤
前列腺癌
发表日期：2025
文献求助 收藏

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?

阿比特龙、奥特罗内、恩扎卢胺和多西他赛：序贯治疗还是联合治疗？

期刊:Frontiers in Pharmacology
影响因子:4.8
doi:10.3389/fphar.2022.843110
Chen, Ming-Kun; Liang, Zhi-Jian; Luo, Dao-Sheng; Xue, Kang-Yi; Liao, De-Ying; Li, Zheshen; Yu, Yuzhong; Chen, Zhe-Sheng; Zhao, Shan-Chao
发表日期：2022
文献求助 收藏

Fabrication of a hyaluronic acid conjugated metal organic framework for targeted drug delivery and magnetic resonance imaging

构建透明质酸共轭金属有机框架用于靶向药物递送和磁共振成像

期刊:RSC Advances
影响因子:4.6
doi:10.1039/c7ra12969f
Shu, Fangpeng; Lv, Daojun; Song, Xian-Lu; Huang, Bin; Wang, Chong; Yu, Yuzhong; Zhao, Shan-Chao
发表日期：2018
文献求助 收藏